Ramadan Fasting in a Patient with Chronic Myeloid Leukemia Receiving Nilotinib as Upfront
journal contribution
submitted on 2024-11-26, 11:09 and posted on 2024-11-26, 11:09 authored by Husam N. Al-Dubai, Mohammed A. Yassin, Mohammed A. Abdulla, Mahmood S. Aldapt, Rola S. GhassoubChronic myeloid leukemia (CML) is a myeloproliferative neoplasm classically described as triphasic disease: chronic, accelerated, and blast crisis. There are many unmet needs and unanswered questions about CML. Intermittent fasting in patients with CML on tyrosine kinase inhibitors is among these unmet needs. Here we report the effect of intermittent fasting on response to nilotinib as upfront in a 49-year-old female Muslim who fasted during Ramadan and took her medication once instead of twice daily and remained in major molecular response.
Other Information
Published in: Case Reports in Oncology
License: https://creativecommons.org/licenses/by-nc/4.0/
See article on publisher's website: https://dx.doi.org/10.1159/000507508
Funding
Open Access funding provided by the Qatar National Library.
History
Language
- English
Publisher
KargerPublication Year
- 2020
License statement
This Item is licensed under the Creative Commons Attribution-NonCommercial 4.0 International LicenseInstitution affiliated with
- Hamad Medical Corporation
- Hamad General Hospital - HMC
- National Center for Cancer Care and Research - HMC
